National Precision Medicine Alliance (NPMA)

Tuesday, April 19th, 4 PM | Virtual meeting



Dr Ong Choon Kiat

National Cancer Centre Singapore

Talk Title:
SYMPHONY LCG programme – Orchestrated Research from Discovery to Improve Treatment Outcomes



Dr Niranjan Nagarajan

Genome Institute of Singapore

Talk Title:
Singapore Platinum Metagenomes Project (SPMP)



Dr Danny Soon

CRIS Singapore

Talk Title:
Innovative Research at a National Level

RSVP NOW



Host

Prof Patrick Tan
Executive Director, Genome Institute of Singapore
Director, NPM Programme Coordinating Office, A*STAR

Organised by: NPM Programme Coordinating Office, A*STAR

Genome Institute of Singapore
GIS

National Precision Medicine Alliance (NPMA)

Tuesday, April 19th, 4 PM | Virtual meeting

Agenda
SYMPHONY LCG programme – Orchestrated Research from Discovery to Improve Treatment Outcomes ***Dr Ong Choon Kiat*** Principal Investigator, National Cancer Centre Singapore
Singapore Platinum Metagenomes Project (SPMP) ***Dr Niranjan Nagarajan*** Associate Director, Genome Institute of Singapore
Innovative Research at a National Level ***Dr Danny Soon*** Chief Executive Officer, Consortium for Clinical Research and Innovation Singapore Executive Director, Singapore Clinical Research Institute



Dr Ong Choon Kiat

Principal Investigator
Lymphoma Genomic Translational Research Laboratory
Division of Cellular and Molecular Research
National Cancer Centre Singapore
Associate Professor
Cancer and Stem Cell Biology Research
Duke-NUS Medical School

Dr. Ong Choon Kiat is the Principal Investigator of Lymphoma Genomic Translational Research Laboratory, National Cancer Centre Singapore (NCCS). He also holds a co-appointment as an associate professor at the Duke-NUS medical school. Dr. Ong obtained his BSc (Hon) in 2000 and PhD in 2006 from the National University of Singapore. Dr. Ong has led the genomic research in various cancers prevalent in Asia including cholangiocarcinoma, fibroepithelial tumors of the breast, and T and NK-cell lymphoma. Dr Ong, along with other collaborating scientists in the field of cancer research, was awarded the "AACR Team Science Award 2018" by the American Association for Cancer Research (AACR), recognising the outstanding interdisciplinary team's work in furthering the knowledge of Asian prevalent cancers, at the same time contributing to the progress of cancer detection, treatment and prevention. His current interest is to improve the clinical outcome of lymphomas' patients through the understanding of cancer genomics and translating the findings into clinical applications.

I will give an overview of the SYMPHONY LCG programme and describe how the team collaborated and work together as One. I will share some examples how we use various research strategies to understand the various subtypes of lymphoma, especially those prevalent in Asia and translating these findings into clinical application, improving treatment outcomes.



Dr Niranjan Nagarajan

Associate Director
Genome Architecture & Design
Senior Group Leader (Laboratory of Metagenomic Technologies & Microbial Systems
Associate Professor
Department of Medicine & School of Computing
National University of Singapore

Dr. Nagarajan is Associate Director and Senior Group Leader in the Genome Institute of Singapore, and Associate Professor in the Department of Medicine and Department of Computer Science at the National University of Singapore. His research focuses on developing cutting edge genome analytic tools and using them to study the role of microbial communities in human health. His team conducts research at the interface of genetics, computer science and microbiology, in particular using a systems biology approach to understand host-microbiomepathogen interactions in various disease conditions. Dr. Nagarajan received a B.A. in Computer Science and Mathematics from Ohio Wesleyan University in 2000, and a Ph.D. in Computer Science from Cornell University in 2006 (Advisor: Prof. Uri Keich). He did his postdoctoral work in the Center for Bioinformatics and Computational Biology at the University of Maryland working on problems in genome assembly and metagenomics (Advisor: Prof. Mihai Pop).



Dr. Danny Soon

Chief Executive Officer
Consortium for Clinical Research and Innovation, Singapore
Executive Director
Singapore Clinical Research Institute

Dr. Danny Soon is Chief Executive Officer at the Consortium for Clinical Research and Innovation, Singapore (CRIS) and concurrent Executive Director at the Singapore Clinical Research Institute (SCRI). As the inaugural CEO, Danny has the responsibility of bringing together five research programmes and platforms under the auspices of CRIS, promulgating synergies and strategies, building corporate functions to service the entire entity.

Danny was previously the Executive Director of Biomedical Research Council (BMRC) in A*STAR. His team in BMRC was responsible for incepting and coordinating efforts and programmes in drug development, precision medicine, medical technology and biomanufacturing. Previously, Danny also held the role of founding and Acting CEO of the Experimental Biotherapeutics Centre. In this role, where he and his team were responsible for setting up a brand new centre for biotherapeutics development.

Danny has long experience in drug development, having worked at Eli Lilly and Company for 15 years, where he headed up the Lilly-NUS Centre for Clinical Pharmacology (LNUS). As the Managing Director and Principal Investigator, Danny had responsibility and oversight for all clinical Phase 1 studies conducted and operations in the unit. Studies conducted included first-in-human studies, biomarker development work, human physiology investigations and pivotal registration PK studies, in neuroscience, diabetes, musculoskeletal and cardiovascular therapeutic areas.